WO1996029423A1 - Compositions et methodes pour induire une infection par des vecteurs retroviraux en dehors de leur gamme d'hotes - Google Patents
Compositions et methodes pour induire une infection par des vecteurs retroviraux en dehors de leur gamme d'hotes Download PDFInfo
- Publication number
- WO1996029423A1 WO1996029423A1 PCT/US1996/002015 US9602015W WO9629423A1 WO 1996029423 A1 WO1996029423 A1 WO 1996029423A1 US 9602015 W US9602015 W US 9602015W WO 9629423 A1 WO9629423 A1 WO 9629423A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retrovirus
- cells
- adenovirus
- infection
- virus
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 21
- 239000013598 vector Substances 0.000 title abstract description 60
- 230000001177 retroviral effect Effects 0.000 title abstract description 55
- 208000015181 infectious disease Diseases 0.000 title description 64
- 230000001939 inductive effect Effects 0.000 title description 3
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 115
- 241000701161 unidentified adenovirus Species 0.000 claims abstract description 114
- 238000009472 formulation Methods 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 108090000565 Capsid Proteins Proteins 0.000 claims description 6
- 102100023321 Ceruloplasmin Human genes 0.000 claims description 6
- 108090001030 Lipoproteins Proteins 0.000 claims description 5
- 102000004895 Lipoproteins Human genes 0.000 claims description 5
- 101710173835 Penton protein Proteins 0.000 claims description 4
- 101710154606 Hemagglutinin Proteins 0.000 claims description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 3
- 101710176177 Protein A56 Proteins 0.000 claims description 3
- 239000000185 hemagglutinin Substances 0.000 claims description 3
- 241000712461 unidentified influenza virus Species 0.000 claims description 3
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 210000004027 cell Anatomy 0.000 description 193
- 241000700605 Viruses Species 0.000 description 60
- 108020003175 receptors Proteins 0.000 description 39
- 102000005962 receptors Human genes 0.000 description 37
- 241001529936 Murinae Species 0.000 description 29
- 239000002245 particle Substances 0.000 description 26
- 210000005260 human cell Anatomy 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 16
- 210000003494 hepatocyte Anatomy 0.000 description 12
- 150000007523 nucleic acids Chemical class 0.000 description 12
- 238000004806 packaging method and process Methods 0.000 description 12
- 206010038997 Retroviral infections Diseases 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000003993 interaction Effects 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 230000002463 transducing effect Effects 0.000 description 11
- 230000003612 virological effect Effects 0.000 description 10
- 230000002950 deficient Effects 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 230000001566 pro-viral effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 108700004025 env Genes Proteins 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 7
- 241000283984 Rodentia Species 0.000 description 7
- 101150030339 env gene Proteins 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 241000714177 Murine leukemia virus Species 0.000 description 6
- NFGODEMQGQNUKK-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 NFGODEMQGQNUKK-UHFFFAOYSA-M 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000937642 Homo sapiens Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Proteins 0.000 description 5
- 102100027329 Malonyl-CoA-acyl carrier protein transacylase, mitochondrial Human genes 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 101800001271 Surface protein Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000010415 tropism Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- SVDVJBWDBYSQLO-UHFFFAOYSA-N 5-(4-hydroxy-3-methoxyphenyl)-5-phenylimidazolidine-2,4-dione Chemical compound C1=C(O)C(OC)=CC(C2(C(NC(=O)N2)=O)C=2C=CC=CC=2)=C1 SVDVJBWDBYSQLO-UHFFFAOYSA-N 0.000 description 4
- 208000003322 Coinfection Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 101150067824 MCAT gene Proteins 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- -1 cationic amino acid Chemical class 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000012202 endocytosis Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000007502 viral entry Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 2
- 206010060931 Adenovirus infection Diseases 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 241001135569 Human adenovirus 5 Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010085012 Steroid Receptors Proteins 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000010187 selection method Methods 0.000 description 2
- 102000005969 steroid hormone receptors Human genes 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010001258 Adenoviral infections Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108050005273 Amino acid transporters Proteins 0.000 description 1
- 102000034263 Amino acid transporters Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
- 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
- 241000406206 Ecotropic murine leukemia virus Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000009025 Endorphins Human genes 0.000 description 1
- 108010049140 Endorphins Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 101100356020 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) recA gene Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010036012 Iodide peroxidase Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 101100042680 Mus musculus Slc7a1 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 108010013639 Peptidoglycan Proteins 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 102100024819 Prolactin Human genes 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 102000014267 Thyroid peroxidases Human genes 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 241000713893 Xenotropic murine leukemia virus Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940076002 angiogenesis modulator Drugs 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 210000002806 clathrin-coated vesicle Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000001159 endocytotic effect Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108010084724 gibbon ape leukemia virus receptor Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 102000012498 secondary active transmembrane transporter activity proteins Human genes 0.000 description 1
- 108040003878 secondary active transmembrane transporter activity proteins Proteins 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Definitions
- mixture of a retrovirus and adenovirus is meant a formulation comprising the retrovirus and adenovirus which is administered to an organism or cell simultaneously or the administration of a retrovirus and adenovirus separately, but in close temporal order such that the organism or cell will be exposed to both the retrovirus and adenovirus at substantially the same time.
- nucleic acid By nucleic acid is meant both RNA and DNA including: cDNA, genomic DNA, plasmid DNA or condensed nucleic acid, nucleic acid formulated with cationic lipids, nucleic acid formulated with peptides, cationic polymers, RNA or mRNA.
- the nucleic acid administered is plasmid DNA which comprises a vector, phosphoproteins.
- Data are expressed as the apparent titer of the xenotropic retrovirus on the NIH3T3 cells (y-axis) as a function of the concentration of adenovirus (x-axis) , and dilution of the retrovirus stock
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention décrit des méthodes et des compositions pour augmenter la gamme des hôtes d'un rétrovirus ou d'un vecteur rétroviral administré à une cellule ou à un organisme par coadministration d'une formulation contenant, par exemple, un adénovirus. La gamme des hôtes des rétrovirus écotrope, xénotrope et amphotrope peut donc être élargie.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40858695A | 1995-03-20 | 1995-03-20 | |
US08/408,586 | 1995-03-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996029423A1 true WO1996029423A1 (fr) | 1996-09-26 |
Family
ID=23616885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/002015 WO1996029423A1 (fr) | 1995-03-20 | 1996-02-13 | Compositions et methodes pour induire une infection par des vecteurs retroviraux en dehors de leur gamme d'hotes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1996029423A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358742B1 (en) | 1996-03-25 | 2002-03-19 | Maxygen, Inc. | Evolving conjugative transfer of DNA by recursive recombination |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993007283A1 (fr) * | 1991-09-30 | 1993-04-15 | Boehringer Ingelheim International Gmbh | Composition d'insertion de complexes d'acides nucleiques dans des cellules eucaryotes superieures |
WO1994006923A1 (fr) * | 1992-09-24 | 1994-03-31 | The University Of Connecticut | Modification d'un virus pour rediriger l'infectivite et amplifier l'apport cible de polynucleotides a des cellules |
WO1994017832A1 (fr) * | 1993-02-09 | 1994-08-18 | The Scripps Research Institute | Ciblage et transport de genes et d'agents antiviraux dans des cellules par l'adenovirus penton |
-
1996
- 1996-02-13 WO PCT/US1996/002015 patent/WO1996029423A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993007283A1 (fr) * | 1991-09-30 | 1993-04-15 | Boehringer Ingelheim International Gmbh | Composition d'insertion de complexes d'acides nucleiques dans des cellules eucaryotes superieures |
WO1994006923A1 (fr) * | 1992-09-24 | 1994-03-31 | The University Of Connecticut | Modification d'un virus pour rediriger l'infectivite et amplifier l'apport cible de polynucleotides a des cellules |
WO1994017832A1 (fr) * | 1993-02-09 | 1994-08-18 | The Scripps Research Institute | Ciblage et transport de genes et d'agents antiviraux dans des cellules par l'adenovirus penton |
Non-Patent Citations (6)
Title |
---|
ADAMS ET AL: "ADENOVIRAL MEDIATED RETROVIRAL TRANSDUCTION INTO RESISTANT CELLS", ABSTRACTS OF THE AMERICAN SOCIETY FOR CELL BIOLOGY,33RD ANNUAL MEETING, 11 December 1993 (1993-12-11) - 15 December 1993 (1993-12-15), NEW ORLEANS,LOUISIANA, pages 89A, XP002004828 * |
ADAMS ET AL: "INFECTION BY RETROVIRAL VECTORS OUTSIDE OF THEIR HOST RANGE IN THE PRESENCE OF REPLICATION-DEFECTIVE ADENOVIRUS", JOURNAL OF VIROLOGY, vol. 69, no. 3, March 1995 (1995-03-01), pages 1887 - 1894, XP002004830 * |
ADAMS ET AL: "REPLICATION DEFECTIVE ADENOVIRUS ENABLES TRANSDUCTION BY RETROVIRAL VECTORS OF CELLS OUTSIDE OF THEIR HOST RANGE", JOURNAL OF CELLULAR BIOCHEMISTRY,SUPPLEMENT 0,18 PART A, 1994, pages 222, XP000572572 * |
CURIEL ET AL: "ADENOVIRUS ENHANCEMENT OF TRANSFERRIN-POLYLYSINE-MEDIATED GENE DELIVERY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES,USA, vol. 88, October 1991 (1991-10-01), pages 8850 - 8854, XP002004829 * |
DONG ET AL: "A CHIMERIC AVIAN RETROVIRUS CONTAINING THE INFLUENZA VIRUS HEMAGGLUTININ GENE HAS AN EXPANDED HOST RANGE", JOURNAL OF VIROLOGY, vol. 66, no. 12, December 1992 (1992-12-01), pages 7374 - 7382, XP000572226 * |
MOLECULAR BIOLOGY OF THE CELL, vol. 4, October 1993 (1993-10-01) * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358742B1 (en) | 1996-03-25 | 2002-03-19 | Maxygen, Inc. | Evolving conjugative transfer of DNA by recursive recombination |
US6387702B1 (en) | 1996-03-25 | 2002-05-14 | Maxygen, Inc. | Enhancing cell competence by recursive sequence recombination |
US6391552B2 (en) | 1996-03-25 | 2002-05-21 | Maxygen, Inc. | Enhancing transfection efficiency of vectors by recursive recombination |
US6482647B1 (en) | 1996-03-25 | 2002-11-19 | Maxygen, Inc. | Evolving susceptibility of cellular receptors to viral infection by recursive recombination |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Smith | Viral vectors in gene therapy | |
EP0702084B1 (fr) | Rétrovirus recombinants | |
JP3565859B2 (ja) | 改良されたアデノウイルスおよびその使用法 | |
JP2752788B2 (ja) | 感染および過剰増殖障害の為の組換え療法 | |
JP2001517452A (ja) | 機能的スプライス・ドナー部位及び機能的スプライス・アクセプター部位を含むレトロウイルスベクター | |
CZ308897A3 (cs) | Virové vektory a jejich použití pro léčení hyperprofilerativních nemocí, zejména restenosy | |
JP4011604B2 (ja) | 後天性疾患治療用の新規移植組織片および新規ベクター | |
JP2002513290A (ja) | 修飾されたファイバー蛋白質を有するアデノウイルスによる遺伝子移入 | |
US20020123146A1 (en) | Highly productive packaging lines | |
JP2001523089A (ja) | 細胞外マトリックス成分に結合する修飾ウイルス表面蛋白質 | |
Havenga et al. | Retroviral stem cell gene therapy | |
JPH10507905A (ja) | ヒト血清による溶解耐性生産者細胞系で生産されるレトロウイルスベクター | |
JPH10501980A (ja) | 核酸の送達におけるまたはそれに関する改良 | |
JPH05505944A (ja) | 修飾肝細胞およびその用途 | |
NZ300795A (en) | Retroviral Plasmid Vectors (enhancer region of LTR replaced, primer binding site replaced or mutated), packaging/transduced cells, use for gene therapy | |
EP1078094B1 (fr) | Methodes et compositions pour la production de particules virales | |
JP3923078B2 (ja) | あらかじめ定まった結合価を持つアダプターを有するウイルスベクター複合体 | |
Dickson | Molecular and cell biology of human gene therapeutics | |
WO2000017376A1 (fr) | Systeme de vecteur retroviral presentant une deficience de replication, et procedes d'utilisation associes | |
WO2000078987A1 (fr) | Vecteur d'expression de deux genes etrangers | |
US20070042494A1 (en) | Heterologous retroviral packaging system | |
WO1996029423A1 (fr) | Compositions et methodes pour induire une infection par des vecteurs retroviraux en dehors de leur gamme d'hotes | |
Adams et al. | Infection by retroviral vectors outside of their host range in the presence of replication-defective adenovirus | |
US6762031B2 (en) | Targeting viral vectors to specific cells | |
EP1163912A1 (fr) | Therapeutique genique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |